<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
16.04.2019 13:27:00

Is Alnylam Pharmaceuticals a Buy Now?

Biotech investors who let go of their Alnylam Pharmaceuticals (NASDAQ: ALNY) shares after a disappointing trial failure in late 2016 must be kicking themselves right now. The stock has risen 150% since safety concerns put an end to one of its most advanced new drug candidates at the time.Last summer, the FDA approved Alnylam's first new drug, and a handful of late-stage candidates aren't far behind. The company is still losing heaps of money, but investors enthusiastic about its pipeline have inflated Alnylam's market value to $9.7 billion at recent prices. Let's look at what lies ahead to see if the company can meet some lofty expectations and deliver further gains.Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Alnylam Pharmaceuticals Inc.mehr Analysen

01.10.18 Alnylam Pharmaceuticals Overweight Cantor Fitzgerald
13.08.18 Alnylam Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
07.08.18 Alnylam Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
05.07.18 Alnylam Pharmaceuticals Buy Chardan Capital Markets
04.05.18 Alnylam Pharmaceuticals Hold Stifel, Nicolaus & Co., Inc.

Eintrag hinzufügen

Proteste in Hongkong: Mögliche Folgen für die Aktienmärkte

Aktien in diesem Artikel

Finanzen.net News

pagehit